Filing identity and reporting period
The supplied filing is Inpixon’s unaudited Form 10-Q for the quarter ended March 31, 2021—not a filing for XTI Aerospace, Inc. Investors should verify the issuer before relying on this summary. Inpixon describes itself as an indoor-intelligence company serving business and government customers with positioning, mapping, analytics, and related software and hardware.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | $2.954 million | $1.804 million; up 64% |
| Gross profit and margin | $2.070 million; 70% | $1.294 million; 72% |
| Operating expenses | $14.490 million | $6.860 million |
| Operating loss | $12.420 million | $5.566 million |
| Net loss attributable to Inpixon stockholders | $12.557 million; $0.16 per share | $6.158 million; $1.22 per share |
| Adjusted EBITDA (non-GAAP) | Loss of $5.557 million | Loss of $3.885 million |
| Cash used in operating activities | $5.661 million | $4.535 million |
At March 31, 2021, cash was $46.273 million and short-term investments were $50.057 million, mostly U.S. Treasury bills. Working capital was approximately $88.9 million. Short-term debt was $4.251 million, consisting of a 10% note with a March 2022 maturity; lease liabilities totaled $1.976 million. Total liabilities were $12.909 million. Cash and cash equivalents increased $28.277 million during the quarter.
Material changes and financing
- Revenue growth was attributed mainly to Systat software and RTLS product sales, including products added through acquisitions. Recurring revenue was $1.409 million versus $0.862 million; non-recurring revenue was $1.545 million versus $0.942 million.
- Gross margin declined from 72% to 70%, which management attributed primarily to lower margins in RTLS.
- Operating expenses rose $7.630 million. Management cited about $2.0 million related to the Systat license and Nanotron acquisition and about $4.7 million of additional stock-based compensation. Quarterly stock-based compensation was $5.096 million versus $0.399 million.
- Three registered direct offerings and warrant exercises contributed approximately $77.9 million in net financing proceeds. Common shares issued and outstanding increased from approximately 53.2 million at December 31, 2020 to 101.4 million at March 31, 2021; the filing also reports 111.8 million shares outstanding on May 14. Potential dilution includes warrants, options, and restricted stock.
- Investing cash outflow was $43.321 million, primarily reflecting $42.059 million invested in short-term investments. Financing cash inflow was $77.269 million.
Outlook, risks, and unusual items
- Management said available cash and budgeted cash flows were expected to support operations for the next 12 months from the financial statements’ issuance date. The filing provides no specific revenue or earnings guidance and cautions that continued losses and future financing needs remain possible.
- COVID-19 effects remained uncertain. The company reported supply-chain cost increases and component delays, as well as customer demand weakness and project delays, and said hardware supply constraints could continue.
- Management’s strategy emphasized acquisitions to expand its indoor-intelligence offerings. After quarter-end, it reported acquisitions or transactions involving Game Your Game, Visualix, and The CXApp; the CXApp consideration included approximately $22.5 million in cash, 8.82 million Inpixon shares, and potential earnout payments of up to $12.5 million.
- After quarter-end, Sysorex agreed to settle approximately $9.1 million owed to Inpixon with Sysorex shares and rights to acquire additional shares. The receivable had valuation allowances, and its collectability and the value and liquidity of settlement securities warrant attention. The CEO had disclosed relationships with Sysorex.
- The company reported no material pending legal proceedings apart from ordinary routine litigation. It warned of risks including continued losses, acquisition integration, competition and technology changes, financing access, COVID-related impacts, and Nasdaq listing compliance.
- The filing reports effective disclosure controls as of quarter-end and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer: this is an Inpixon filing, not an XTI Aerospace filing.
- Assess whether revenue growth can translate into improved margins and reduced operating losses, given the rising expenses and cash used in operations.
- Review the effects of the large equity and warrant issuances on dilution, including outstanding warrants and subsequent share counts.
- Verify liquidity after quarter-end acquisitions and other cash commitments, and assess the assumptions behind management’s 12-month liquidity statement.
- Evaluate the collectability and realizable value of the Sysorex settlement and the related-party governance considerations.
- Track acquisition performance, integration costs, earnout obligations, and impairment risks for acquired goodwill and technology assets.